Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia. Molica S, Allsup DJ, Polliack A. Leuk Lymphoma 2022 Jun 15:1-3. doi: 10.1080/10428194.2022.2087072.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Molica S, Allsup DJ, Polliack A. Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia. Leuk Lymphoma 2022 Jun 15:1-3. doi: 10.1080/10428194.2022.2087072.
PMID: 35703117